title: Therapeutic advances: donepezil for the treatment of Alzheimer's disease.
abstract: Until recently, few drugs have been available for the treatment of Alzheimer's disease. The first such drug to be launched in the U.K. was the acetylcholinesterase inhibitor, donepezil. The limited published data on donepezil shows only modest cognitive benefit in patients with Alzheimer's disease. The cost of diagnosis and drug treatment, the distressing nature of the disease and the limited evidence available, pose difficult decisions for the introduction of new drugs and the management of this condition.
authors.affiliation: Department of Medicines Management, Keele University, UK.
authors.forename: J
authors.initials: J
authors.lastname: Misson
authors.forename: M J
authors.initials: MJ
authors.lastname: Kendall
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000191:economics; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects*; D000075202:Contraindications; D000077265:Donepezil; D004347:Drug Interactions; D016903:Drug Monitoring; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D009475:Neurons, Afferent / Q000187:drug effects / Q000473:pathology; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D006113:United Kingdom
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil